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Abstract: The aim of this study was to understand the effect of high shear homogenization (HSH)
and ultrasonication (US) on the physicochemical properties of blank and olanzapine loaded nanos-
tructured lipid carriers (NLCs) along with their drug loading potential and drug release profiles
from formulated particles. NLCs were prepared with different ratios of Compritol and Miglyol as
the solid and liquid lipids, respectively, under changing HSH and US times between 0 to 15 min.
The surfactants (Poloxamer 188 (P188) and tween 80) and the drug content was kept constant in
all formulations. The prepared NLCs were evaluated for particle size, polydispersity index, zeta
potential, drug crystallinity and chemical interactions between lipids and OLZ. The in-vitro drug
release was performed using dialysis tube method in phosphate buffer solution (PBS) at pH 7.4. The
formulated NLCs were negatively charged, spherically shaped and monodisperse, with particle
sizes ranging from 112 to 191 nm. There was a significant influence of US time on the preparation of
NLCs in comparison to HSH, where a significant reduction in the mean particle diameter was seen
after 5 min of sonication. An increase of Miglyol content in NLCs led to an increase in particle size.
In general, application of US led to decrease in particle size after HSH but an increase in particle
diameter of low Miglyol containing preparation was also observed with longer sonication time. OLZ
was successfully encapsulated in the NLCs and a total release of 89% was achieved in 24 h in PBS
at pH 7.4.
Keywords: nanostructured lipid carriers; ultrasonication; high shear homogenization; olanzapine
1. Introduction
The need for suitable alternatives to conventional drug delivery systems has led
to a rising interest in lipid-based formulations. In particular, lipid nanoparticles (LNPs)
are known to have a high drug encapsulation efficiency, high stability and are generally
inexpensive to produce [1]. Additionally, as these lipid systems can be prepared without
organic solvents and are made up of lipids similar to those found in the human body,
hence they are considered to be biocompatible, biodegradable and non-toxic [1,2]. Solid
lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) are two main types of
LNPs [1].
Both lipid systems are prepared using pure lipids or a blend of lipidic compounds
(e.g., triacylglycerols, fatty acids and oils), and a single surfactant (or combined with a
co-surfactant) surrounding the particles. The formulation technique and lipid structure
typically define several LNP characteristics, including the particle size and size distribution,
the drug loading capacity and the encapsulation efficiency [3]. The solid lipid composition
(Figure 1) of SLNs results in their perfect crystalline core, which often results in less space
available for drug loading. On the other hand, NLCs are made up of both liquid and solid
lipids resulting in a more amorphous matrix and less dense lipid packaging. This allows
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NLCs to have a higher drug encapsulation, minimal drug leakage and long-term storage
stability in comparison to SLNs [4–6].
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tation compared to the control experiment [7]. NLC’s have also been used for increasing 
the bioavailability of orally administered drugs by enhancing their uptake through the 
lymphatic system (M-cells in the intestinal membrane) and bypassing the first pass me-
tabolism [8]. Chun-Yang Z. et al. 2010 prepared vinpocetine NLC formulation to estimate 
the potential of NLC as an oral delivery system for poorly water-soluble drugs. Their oral 
bioavailability study of the formulation, carried out using Wistar rats, revealed a 322% 
increase in drug concentration compared to the pure drug suspension [9]. Furthermore, 
Joshi M. et al. 2008 prepared NLCs containing artemether, a poorly water-soluble antima-
larial agent. Their formulation ‘Nanoject’ was investigated in mice which showed signifi-
cantly higher (p < 0.005) antimalarial activity as compare to the marketed injectable for-
mulation [10]. 
 
Figure 2. Applications of NLC’s as drug delivery systems. 
Usage of the NLCs in ocular drug delivery has also been investigated to enhance pre-
corneal retention time. Shen et al. 2010 prepared mucoadhesive NLC’s modified by thio-
lated agent which resulted in low systemic cyclosporine concentration but significantly 
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higher residence time in aqueous humor, tear and ocular tissues than that of oil solution and
non-thiolated NLCs (p < 0.05) [11]. Furthermore, Alam et al. 2012 prepared bromocriptine
incorporated NLCs for the controlled delivery of drug to provide extended therapeutic
effects for the treatment of Parkinson’s disease. Their drug loaded NLCs were found
to be longer lasting (5 h more efficacy) compared to the non-encapsulated counterpart.
Such beneficial applications of NLC’s also been achieved in the field of pulmonary drug
delivery [12], delivery of chemotherapeutic agent [13,14] and gene delivery to actively
suppress tumor growth or treat cancer [15,16].
The lipids used to prepare NLCs are usually triglycerides, fatty acids, waxes and par-
tial glycerides. In this work, we prepared NLCs using Compritol® 888 ATO and Miglyol as
these are considered GRAS substances and are commonly used to formulate LNPs [4,17–19].
Moreover, both excipients are cheap, widely available, highly biocompatible, highly stable
and able to incorporate a range of pharmaceutical actives or cosmetics [17,18]. Another
reason behind the choice of Compritol® as the solid lipid was its neutral cytotoxic behavior
and its ability to solubilize Olanzapine (OLZ) [18,19].
OLZ was selected as the model drug for encapsulation into the formulated NLCs. OLZ
is an essential atypical anti-psychotic agent that is effective in the treatment of schizophre-
nia [20]. OLZ is lipophilic, which means that it is highly permeable through biological
membranes but suffers from low oral bioavailability due to poor aqueous solubility and
extensive first pass metabolism [21]. Therefore, it is important to design a pharmaceutical
system which provides a better dissolution rate and potentially results in higher OLZ
bioavailability. Various methods have been investigated to help improve the oral delivery
and controlled release of OLZ including the use of lipid-based carriers [21–23].
There are many formulation approaches for LNP formulation including solvent emul-
sification/evaporation, supercritical fluid extraction of emulsions, high pressure homog-
enization and spray-drying [24]. In this study, we employ a combination of high shear
homogenization (HSH) and ultrasonication (US) for the production of OLZ-loaded NLCs.
Both HSH and US are cost-effective methods that can be easily applied to the production
of lipid nanosystems. However, these techniques can have some drawbacks, particularly
associated with long processing times [25]. The impact of processing time on the properties
of LNPs (e.g., influence on particle size) when these two techniques are used either in
isolation or combination are hard to find. Therefore, the objective of this study was to
understand the effect of HSH and US processing time on the physicochemical properties
including particle size, polydispersity index (PDI) and surface charge of NLCs so that the
production of LNPs can be optimized efficiently.
The aim of this study was to understand the effect of HSH and US on the development
of NLCs containing Compritol® and Miglyol and its effect on the particle size and surface
charge. The feasibility to encapsulate OLZ into these NLCs was also explored to improve
dissolution rate of the drug using these formulations. In this study, Compritol® 888 ATO
was used as the solid and Miglyol 812 N as liquid lipid along with the binary mixture of
Poloxamer 188 and Tween 80 surfactants.
2. Materials and Methods
2.1. Materials
Olanzapine, Poloxamer 188 (Pluronic F68), Tween 80 (Polysorbate 80), Disodium
hydrogen phosphate (Na2HPO4) and Potassium dihydrogen phosphate (KH2PO4) were
purchased from Sigma Aldrich, Gillingham, UK. Compritol® 888 ATO (glyceryl behenate)
is a mixture of mono-, di- and triesters of behenic acid (C22), and was obtained from
Gattefossè, La Défense, France. Miglyol 812 N (caprylic/capric triglycerides) was provided
by IOI Oleochemicals, Hamburg, Germany. All other chemical reagents used were of
analytical grade.
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2.2. Methods
2.2.1. Preparation of Blank and OLZ-Loaded NLCs
For this study, a combination of HSH and US was applied to produce blank and drug-
loaded NLCs. To study the effects of both preparation techniques on the morphological
and surface characteristics of NLCs, the total lipid content [Compritol® 888 ATO (C888)
and Miglyol 812 N (Mig)] and the amount of surfactant [Poloxamer 188 (P188) and tween
80] were kept constant at 300 mg and 200 mg, respectively. The volume of aqueous media
(40 mL) and quantity of OLZ (20 mg) also remained consistent for all experiments. Prior
to the formulation of NLCs, both the lipid phase (C888 + Mig) and aqueous phase (P188
+ tween 80 + distilled water) were heated separately at 85 ◦C to allow a complete melt of
the excipients. For drug loaded NLCs, OLZ was added to the lipid phase after heating
to minimize drug degradation. Subsequently, the aqueous phase was combined with the
lipid mixture under high-speed stirring at 24,000 rpm using an UltraTurrax® T25 (IKA
Company, Oxford, UK). The resulting emulsion was then processed using ultrasonic probe
sonicator (Hielscher UP400St, Hielscher Ultrasonics, Teltow, Germany) at 200 W, followed
by cooling in an ice bath for 10 min to solidify the lipid matrix and produce NLCs.
The percentage ratios (Table 1) of solid to liquid lipid were varied between 5 to 50%
based on the weight of solid lipid. The HSH and US time were also altered between 0 to
15 min to understand the impact of processing time on the particle size and surface charge.
Table 1. Description for the quantities of excipients used for NLC formulations.
Formulation C888 (mg) Mig (mg) P188 (mg) Tween 80 (mg)
F5 285 15 150 50
F15 255 45 150 50
F30 210 90 150 50
F50 150 150 150 50
2.2.2. Determination of Particle Size, PDI and Zeta Potential
These measurements were carried out to determine the size and surface charge of
the NLCs. The average particle sizes and PDI were measured by dynamic light scattering
(DLS) using a Zetasizer Nano-ZS (Malvern Instruments Ltd., Malvern, UK). The instrument
was equipped with a laser emitting at 633 nm, and backscattering detection was set at an
angle of 173◦. Samples were prepared by diluting 10 µL of NLC suspensions with 2 mL of
deionized water previously filtered through a 0.2 µm syringe filter. The measurements were
carried out in triplicate at room temperature (25 ◦C) and results reported as the average
of the three independent measurements. The surface charge of the NLC dispersions was
determined by performing zeta-potential (ζ-potential) measurements with the Zetasizer
Nano-ZS at 25 ◦C. The ζ-potential was automatically calculated from the electrophoretic
mobility based on Smoluchowski’ equation.
2.2.3. Bright Field Scanning Transmission Electron Microscopy (BF-STEM)
The BF-STEM was performed in order to determine the shape and surface morphology
of the NLCs. Prior to this analysis, the samples were stained with 2% phosphotungstic acid
solution to provide a clearer view of the NLCs. A drop of the stained NLC dispersion was
placed on the sample stub, making sure to remove any overflowing suspension. Thereafter,
the stub was mounted onto the sample holder and placed inside the Hitachi SU8030
(Hitachi High-Technologies, Maidenhead, UK) scanning electron microscope. Micrographs
were collected in transmission mode at a voltage of 30.0 kV.
2.2.4. Attenuated Total Reflectance-Fourier Transform Infrared (ATR-FTIR) Spectroscopy
The ATR-FTIR spectra of prepared NLCs were obtained using a Spectrum Two FTIR
spectrometer (Perkin Elmer, Beaconsfield, UK). The sample was spread uniformly on
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the surface of a single reflection horizontal ATR accessory with a zinc selenide (ZnSe)
crystal. The spectra were collected from 3450–450 cm−1 range in transmission mode.
Approximately 16 scans were collected for each spectrum with a resolution of 8 cm−1.
2.2.5. X-Ray Diffraction (XRD) Analysis
The crystallinity of freeze-dried NLCs was examined by performing XRD analysis
using a Bruker D8 Advance (Bruker GmbH, Karlsruhe, Germany) diffractometer in theta-
theta reflection mode with copper anode. The frozen aqueous NLC dispersions were freeze-
dried under deep vacuum at−55 ◦C using a ScanVac CoolSafe freeze dryer (LaboGene ApS,
Lynge, Denmark). Diffractograms were obtained at room temperature for all samples. For
XRD analysis, samples were sandwiched between two Mylar films and placed in sample
holder. Spectra were collected in transmission mode using CuKα radiations at a scan rate of
0.02 ◦/sec from 2 to 47◦ 2θ values by rotating the sample cell at 15 rpm. Data collection and
interpretations were performed using DiffracPlus and the EVA V.16 program, respectively.
2.2.6. Drug Entrapment Efficiency
Drug entrapment efficiency was determined by an ultrafiltration-centrifugation (cen-
trifugal filters Amicon Ultra-4 with 100 kDa molecular weight cut-off, Millipore, Germany)
based indirect method reported by Cirri et al., 2012 [26]. Briefly, 500 µL of each OLZ-
loaded NLC dispersion was placed into the upper chamber of the ultrafiltration device,
and centrifuged at 12,000 rpm for 30 min. The concentration of unencapsulated drug in
the outer chamber was then spectrophotometrically assayed at 258 nm (Cary 100 UV-Vis
spectrometer, Agilent Technologies, Cheadle, UK). Entrapment efficiency (EE) of OLZ in
nanoparticles was calculated according to Equation (1).
EE% = (Wtotal drug −W f ree drug/Wtotal drug) ∗ 100 (1)
Where, Wtotal drug is the total drug in the formulation and W f ree drug is the amount of
unencapsulated drug after ultrafiltration-centrifugation.
2.2.7. Drug Release Studies
The samples for drug release studies were prepared with 15 min HSH followed by
5 min of US. The in-vitro drug release studies for prepared OLZ-loaded NLCs was per-
formed using dialysis tube method [27]. The dialysis tubes were cut in size and pretreated
by dipping them in pH 7.4 phosphate buffer solution (PBS) for 24 h. The NLC suspension
containing equivalent of 20 mg OLZ was filled in the tubing, and a thread was used to
secure both ends of the tube. Thereafter, the tube was suspended in a beaker containing
200 mL PBS under stirring at 300 rpm and a constant temperature of 37 ± 2 ◦C. At reg-
ular time intervals, 4 mL aliquots of the external medium were removed and replaced
with the same volume of fresh PBS. The withdrawn sample was filtered and analyzed by
ultraviolet-visible (UV-Vis) spectroscopy (Cary 100 UV-Vis spectrometer, Agilent Technolo-
gies, Cheadle, UK) at 258 nm to determine OLZ release. These experiments were carried
out in triplicate. The percentage drug release was determined using the Equation (2):
D% = 100× Cn ×VPBS
Encapsulated drug amount
(2)
Where, D%: drug amount (%), Cn: corrected concentration (mg/mL), VPBS: volume
of PBS in the beaker (mL) and Encapsulated drug amount relates to the total theoretical
amount of the drug to be released (mg).
Drug release data were fitted into zero-order, first-order, Higuchi and Korsmeyer–
Peppas to determine the best fitting kinetic model. The prevalent mechanism of drug
release from NLCs was also inferred from the value of the diffusional release exponent of
the Korsmeyer–Peppas equation.
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2.2.8. Storage Stability Studies
All the selected drug-loaded NLC dispersions were stored at 4 ± 1 ◦C for 6 months
and analyzed every 30 days for mean particle size, PDI and zeta potential Zetasizer Nano-
ZS. Samples were also checked for drug EE% at the end of the storage period, to evaluate
the drug expulsion from NLCs. At least three replicate analyses were done for each sample.
Possible crystallization, precipitation, mold formation or gelling phenomena were also
checked by visual inspection.
3. Results and Discussion
3.1. Effect of Ultrasonication on the Formulation of NLCs
The effect of US on average size, PDI and surface charge of prepared NLCs was
investigated by varying US time between 0 to 15 min whilst keeping HSH time constant to
15 min. The Figure 3 presents the average particle sizes of the NLCs prepared with 5 to
50% Mig by the weight of C888 in the formulation (or F5 to F50).
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It is evi e t fro Figure 3 that S alone as not sufficient to reduce the particle
si e of s, an there as a clear impact of US after homogenization. The particle size
ra ge (148–191 n ) obtained ith S alone as lo ered to 118–164 n ith just 1 in
f S. The contribution of sonication energy to the NLC dispersions led to a breakdown of
coarse emulsion drops into nanoemulsion dr plets and, co seque tly, a decrease in particle
size [28]. G nerally, between 0 to 5 min of US, the particle sizes of prepared NLCs increased
with th rise in Mig content in the formulation, where largest NLCs w re observed with
F50 and smallest with F5 formulations. The increase in size with rising liquid lipid content
can be attributed to the swelling of nanoparticle core to accommodate higher quantities
of Mig in the formulation [29,30]. There is also a possibility of forming more disordered
crystalline structure within the particles at a higher Mig content, subsequently resulting in
the production of larger sized particles [29,31]. After 5 min of US, an increase in particle
size was observed for all formulations. This rise in size with increasing US time was
particularly significant for F5 preparations, where the particle sizes ranged from 112 nm at
5 min to 172 nm at 15 min of US. It is well known that the energy supplied to the phases
during emulsification and the processing time has a huge impact on the particle size and
distribution of lipid particles [32]. In relation to the production of lipid carriers, some
researchers have found that an increase in sonication energy input and processing time
leads to lower particle sizes [33,34]. However, this is also dependent on the composition of
the lipid formulation and the reverse can be obtained in some cases with the mean particle
diameter rising with higher sonication time or energy [35]. This can be attributed to the
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coalescence of small particles into larger ones, which could not be separated or ruptured
into smaller particles with further input of energy [32,35]. Hence, higher input of energy
can be counterproductive especially when dealing with smaller particles as evident for
the NLCs of F5 and F15 formulations as shown in the Figure 3. This study suggested that
5 min of US was sufficient to obtain smallest mean diameters of the NLCs containing C888
and Mig, and any further increase in processing time either led to the increase in particle
sizes or had no further impact.
The PDI of prepared NLCs is presented in Figure 4.
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nee s to be studied carefully for a set of lipids when developing these systems. Figure 5
presents ζ-potential values for the NLCs prepared by the combination of HSH and US.
The ζ-potential is a common measure of particle surface charge and the stability of
a colloidal suspension. In general, higher ζ-potential values indicate a well-suspended
colloidal system that is less likely to aggregate [36]. The negative ζ-potential values
recorded for all formulated NLCs (−23 to −11 mV) was due to the presence of hydrophilic
surfactants on the particle surface [37]. There was a slight decrease in ζ-potential with the
change in particle size, which could be due to the difference in surfactant density on the
particle/droplet surface [36,38].
A set of experiments using F30 formulations were conducted to understand if there
was an impact of change in HSH time on the mean diameter and surface charge of prepared
NLCs. Table 2 presents the results of NLCs formulated with varying HSH time with or
without 5 min of US.
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Interestingly, higher HSH time had no impact on the final particle size, PDI or ζ-
potential and 5 min of both HSH and US appeared to be optimal to prepare these formula-
tions. As observed fro Table 2, at a constant US time of 5 min, there was no significant
change in the particle size, PDI and surface charge of the prepared NLCs with the increase
in HSH time. In general, the formulated lipid carriers had an average size and PDI of
approximately 120 nm and 0.3, respectively. The low PDI value confirms that the NLCs are
monodisperse and have narrow particle size distribution. Thus, it can be concluded that
while HSH is important for the primary emulsification, the particle/droplet size reduction
principally occurs after the application of US in the NLC formulation process.
3.2. Effect of Solid to L quid Lipid Ratio on OLZ Encapsulation
The effect of drug encapsulation in NLCs prepared by varying liquid lipid (5, 10, 20,
30 and 50%) was studied by keeping OLZ amount (20 mg) constant in the formulations.
Table 3 presents the comparison between blank, and drug loaded NLCs with respect to the
mean diameter and PDI.
Table 3. Effect of solid to liquid lipid ratio on the particle size and PDI of blank and drug-
loaded NLCs.
Formulation Blank NLCs PDI OLZ-NLCs PDI
F5 112 (±2.9) 0.30 114 (±4.0) 0.40
F15 123 (±6.6) 0.32 125 (±3.7) 0.40
F30 128 (±2.9) 0.28 123 (±17.7) 0.38
F50 136 (± 0.5) 0.23 123 (± 31.5) 0.33
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At a constant HSH and US processing time of 5 min each, there was a minimal effect
of increasing liquid lipid content on the particle size and PDI of drug-loaded NLCs. The
lack of significant change on the size of drug-loaded particles with increasing amount of
liquid lipid has been previously reported by Teeranachaideekul et al. [39]. The sizes ranged
from 114 to 125 nm with a low PDI (0.33 to 0.40) indicating that formulated NLCs are
mono-disperse and have a narrow particle size distribution. The higher standard deviation
for the mean particle size of F30 and F50 OLZ-loaded formulations can be associated with
the higher liquid lipid content in these systems [40]. In comparison, the recorded PDI and
particle size values for drug loaded NLCs were similar to those for blank NLCs. This can
be due to the solubility of OLZ in the lipid phase, where drugs may be accommodated
within the disordered crystalline lipid structure, resulting in no change into the NLC’s
original morphology [39–41]. Table 4 presents the surface charge data recorded for OLZ-
loaded NLCs prepared with varying Mig content at a constant HSH and US time of 15 and
5 min, respectively.
Table 4. Effect of solid to liquid lipid ratio on surface charge of blank and drug-loaded NLCs.
ζ-Potential (mV)





Similar to particle size and PDI (Table 3), there was a minimal effect of increasing Mig
amount on the ζ-potential of drug-loaded NLCs. The high negative ζ-potential values
recorded for the drug-loaded NLCs indicate that these colloidal suspensions are stable and
less likely to aggregate [36]. Interestingly, the ζ-potential data recorded for drug-loaded
preparations were noticeably higher than those for blank NLCs, which could be attributed
to the presence of OLZ on the surface of the particles. The change in ζ-potential values
after drug encapsulation in NLCs is common and has been reported previously [41–43].
3.3. BF-STEM Analysis and Encapsulation Efficiency
The surface morphology of drug-loaded NLCs was investigated by BF-STEM and is
presented in Figure 6.
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The BF-STEM micrograph (Figure 6) showed that the prepared drug-loaded NLCs
were spherical with a smooth surface. The particle size indicated by BF-STEM imaging
was also similar to the data recorded by DLS for the formulated drug-loaded NLCs. The
encapsulation efficiency (EE) of OLZ increased with the increase in Mig content in the
Sci. Pharm. 2021, 89, 25 10 of 16
formulation. The EE ranged from 33–60% for all formulations with F5 with the lowest
and F50 with the highest. The EE obtained was 33, 36, 41 and 60% for F5, F15, F30 and
F50, respectively. The higher encapsulation efficiency with increased Mig content in the
formulation could be due to the lipophilic nature of OLZ. Although compritol itself is a
long chain fatty acid that can facilitate the entrapment of OLZ in NLC, clearly an increase
in Mig has substantial impact on resulting encapsulation in these formulations [44].
3.4. ATR-FTIR Analysis of OLZ-Loaded NLCs
The structural features of drug-loaded NLCs were studied by performing ATR-FTIR
analysis, and the ATR-FTIR spectra for C888, Mig and OLZ were also collected to allow for
a comparative analysis. As a result of the similarity in their structural composition, both
the solid and liquid lipid do not show many differences in their ATR-FTIR spectra. For Mig
and C888 (Figure 7a), major and common peaks were observed at 2915 and 2849 cm−1 due
to symmetric and asymmetric aliphatic CH2 vibrations, and at 1742 cm−1 as a result of the
presence of carboxylic groups [45,46].
Sci. Pharm. 2021, 89, 25 10 of 16 
 
 
The BF-STEM micrograph (Figure 6) showed that the prepared drug-loaded NLCs 
were spherical with a smooth surface. The particle size indicated by BF-STEM imaging 
was also similar to the data recorded by DLS for the formulated drug-loaded NLCs. The 
encapsulation efficiency (EE) of OLZ increased with the increase in Mig content in the 
formulation. The EE ranged from 33–60% for all formulations with F5 with the lowest and 
F50 with the highest. The EE obtained was 33, 36, 41 and 60% for F5, F15, F30 and F50, 
respectively. The higher encapsulation efficiency with increased Mig content in the for-
mulation could be due to the lipophilic nature of OLZ. Although compritol itself is a long 
chain fatty acid that can facilitate the entrapment of OLZ in NLC, clearly an increase in 
Mig has substantial impact on resulting encapsulation in these formulations [44]. 
3.4. ATR-FTIR Analysis of OLZ-loaded NLCs 
The structural features of drug-loaded NLCs were studied by performing ATR-FTIR 
analysis, and the TR-FTIR spectra for C888, Mig and OLZ were also collected to allow 
for a comparative analysis. As a result of the similarity in their structural composition, 
both the solid and liquid lipid do not show many differences in their ATR-FTIR spectra. 
For Mig and C888 (Figure 7a), major and common peaks were observed at 2915 and 2849 
cm−1 due to symmetric and asymmetric aliphatic CH2 vibrations, and at 1742 cm−1 as a 
result of the presence of carboxylic groups [45,46]. 






Figure 7. (a): ATR-FTIR spectra for Mig and C888. (b) ATR-FTIR spectra for NLCs and unpro-
cessed OLZ. 
In relation to the spectrum obtained for the pure drug, a number of its characteristic 
peaks were observed at 1589 cm−1 (C–N stretching), 1143 cm−1 (aromatic ring stretching), 
964 cm−1 (C–S stretching) and at 749 cm−1 (C–H bond out of plane deformation) [34,35]. 
Figure 7. (a): ATR-FTIR spectra for Mig and C888. (b) ATR-FTIR spectra for NLCs and unpro-
cessed OLZ.
The ATR-FTIR spectra f r unprocessed OLZ and drug-loaded NLCs e presented
in Figure 7 .
In relation o the spectrum obtained for the pure drug, a umber of its characteristic
peaks were observed at 1589 cm−1 (C–N stretching), 1143 cm−1 (aromatic ring stretching),
964 cm−1 (C–S stretching) and at 749 cm−1 (C–H bond out of plane deformation) [34,35].
Meanwhile, the ATR-FTIR spectrum collected for drug-loaded NLCs mostly showed the
characteristic peaks of C888 and Mig, therefore indicating the presence of both lipids in the
formulated NLCs. However, distinct peaks at 963 and 842 cm−1 can also be observed in the
spectrum for the drug-loaded NLCs. Both peaks are not noticeable in the spectra for C888
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and Mig, and also they overlap with the noted band peaks in the spectrum for unprocessed
OLZ. This occurrence can signify the presence of OLZ in the drug-loaded systems.
3.5. XRD Analysis of OLZ-Loaded NLCs
The XRD analysis was performed to investigate possible changes in the crystalline
structure of OLZ during the formulation of NLCs. The X-ray diffraction patterns of the
unprocessed drug, C888, physical mixtures of the lipids/lipids-drug and OLZ-loaded
NLCs are presented in Figure 8.
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The XRD pattern for C888 and C888-Mig mixtures shows two peaks between 19.6 and
24.4◦ 2θ corresponding to the β′ modifications typical of triacylglycerol [47]. The major
diffraction peaks of OLZ appeared in the 2θ range of 8.8 to 30◦, therefore signifying the
crystalline nature of the unprocessed drug [48–50]. The diffractogram of the C888-Mig-
OLZ physical mixture showed peaks at 8.8, 14, 20.8 and 24.1 2θ, values corresponding to
the crystalline OLZ in the mixture, how ver their int nsity was reduced du to the hig
excipients-drug ratio [50]. The diffraction pattern of OLZ-loaded NLCs did not have any
peaks corresponding to OLZ. The peaks at 4.2, 19.1, 2 .2 and 3.3◦ were related to lipids
in the formulation. This may indicate that t e OLZ present in drug-loaded NLCs is in
amorphous form.
3.6. rug elease Studies
The a ount of LZ released fro drug-loaded L s as studied in PBS at p 7.4
using the dialysis tubing method. The dialysis tubing is usually a reliable method to
measure drug release as it is supposed to permit only the exit of the drug and block any
loss of the enclosed particles [36]. The drug release kinetics for OLZ-loaded formulations
prepared with increasing liquid lipid ratio are presented in Figure 9.
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OLZ is a BCS class II drug, and its solubility decreases with the increase in pH. The
dissolution rate and solubility obtained for OLZ form NLCs was higher than the drug alone.
In general, there was a steady and continuous release of OLZ between 0 to 8 h from all
formulations. At 8 h, the amount of drug released from F5, F15, F30 and F50 drug-loaded
formulations were at 71, 73, 70 and 62%, respectively. An impact of the ratio of liquid lipid
was also observed, where increase in Mig in the formulations led to slower and lower drug
releas , particularly evident for formula ion F50 (50% Mig). The highest drug release of
89% was achieved with F5 fter 24 h. The OLZ rel ase reduced from 89% from F5 to 74% for
F50 NLCs at the end of the xperiment. This difference can be attributed to the variations
in the particle size of these formulations that resulted in the changes in specific surface area
required for diffusion of OLZ from lipid core into the release media [51,52]. Additionally,
it is possible that OLZ remains solubilized for longer in formulations containing high
ratios of liquid lipid and preferably stays in the matrix for extended periods before being
released into the media due to its hydrophobic nature. Therefore, the kinetic data suggests
that the NLCs are not only capable of increasing the drug dissolution rate but their liquid
lipid content can also influence the release of incorporated drug. The drug release in this
work was studied only in pH 7.4 PBS, which provides a general overview of the release
behavior along with the i p ct of the ratio b tween solid an liqui lipids as well as
the drug cont nt in the formulation. H wever, it will be ap ropriate to conduct further
studies in simulated gast ic and intestinal fluids to understand the influence of variable
gastrointestinal conditions on the release of olanzapine from NLCs.
Kinetic evaluation of drug release profiles from different NLCs was also performed to
understand the mechanisms governing the drug release. The release data were fitted into
zero order, first order, Higuchi and Korsmeyer–Peppas models. The calculated correlation
coefficients (R2) and release exponent (n) values are presented in Table 5.
Table 5. Correlation coefficients (R2) and release exponent (n) values obtained from the different
kinetic models for NLCs.
Kinetic Model F5 F15 F30 F50
Zero order 0.7972 0.6742 0.5988 0.7219
First order 0.9191 0.8959 0.8759 0.8386
Higuchi 0.9054 0.8357 0.7735 0.879
Korsmeyer-Peppas 0.9751 0.9624 0.9701 0.9861
Korsmeyer-Peppas (n) 0.403 0.355 0.324 0.369
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The best fit for the drug release data from NLCs was obtained for Korsmeyer–Peppas
kinetic model with R2 values ranging from 0.9624 to 0.9861. The value of the diffusional
release exponent (n) of the Korsmeyer–Peppas equation was calculated from Equation (3):
Ft = k× tn (3)
Where, Ft is the drug fraction released at time t, k the release constant and, n the diffu-
sional exponent relates to the mechanism of drug release. n < 0.5 indicates Fickian diffusion;
0.5 < n < 0.9, non-Fickian transport (anomalous transport); and n > 0.9, type-II transport.
The n values for all four formulations were less than 0.5, suggesting a predominantly
diffusion-controlled mechanism of drug release from formulated NLCs.
3.7. Storage Stability Studies
The storage stability of OLZ loaded NLCs was monitored at 4 ◦C for 6 months. The
analysis included basic visual inspection and the determination of physicochemical prop-
erties of the colloidal dispersions. Visual inspection did not show any drug precipitation,
crystallization or mold formation at specified storage condition. The mean particle size
and surface charge of the nanoparticles is presented in Figure 10.
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f charge were detected during the six-month storage period when compared to
the freshly prepared NLCs. Hence, th se results were considered suggestive of the good
phy ical s ability of all four NLCs dispersions pr pared n this study.
4. Conclusions
Spherically shaped and onodispersed NLCs were successfully prepared with C888
(solid lipid) and ig (liquid lipid) using combination of HSH and US techniques, where
processing time and its impact on the properties of NLCs were also investigated. Varying
the US processing time between 1 to 15 min allowed the design of particles with different
size, PDI and surface charge. The particle size obtained after HSH alone was found to
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be 148–191 nm depending on the ratio between solid and liquid lipids, that decreased to
118–164 nm after just 1 min of US. There was also an increase in mean diameter with higher
liquid lipid content in the NLC. For example, NLCs containing 5% liquid lipid resulted in
particles with 118 nm in comparison to 191 nm for formulations containing 50% of Mig.
The influence of increasing liquid lipid ratio on the particle size was not considerable when
US processing time was extended after HSH. There was a minimal effect of longer HSH
time on the properties of NLCs as 15 min of HSH did not result in the further reduction of
particle size. On the other hand, US of 5 min was sufficient to reduce the particle size in all
cases, further energy input beyond 5 min resulted in the coalescence of smaller particles
that was particularly evident for the NLCs with lower Mig ratios.
OLZ was successfully encapsulated by the lipid systems, with little or no effect of
increasing Mig ratio on the particle size and PDI of drug-loaded NLCs. An increase in
ζ-potential values was observed for OLZ loaded NLCs that indicated incorporation of the
drug in the formulation. This may also suggest presence of drug on the particle surface, but
lack of diffraction peaks related to OLZ in XRD spectrum suggested otherwise. A steady
and continuous release of drug from the OLZ-loaded lipid systems was recorded in PBS at
pH 7.4 in 24 h, with a maximum drug release of 89% achieved in formulations prepared
with 5% liquid lipid in the formulation that was approximately nine-fold higher than the
drug alone. The in-vitro release in this study was performed only in pH 7.4 PBS that
provided a general overview of the drug release from formulated NLCs. In future studies,
it would be useful to determine the drug release profiles in simulated gastric and intestinal
environments to establish the suitability of these formulations for oral administration.
The release data obtained from this work indicated that liquid lipid content in NLCs
can influence the release of loaded drugs and it is important to study the processing
parameters carefully when using US in combination with HSH whilst developing a protocol
for NLP preparation. The NLCs prepared in this study showed good stability at 4 ◦C for
six months as no significant changes in the values of average particle sizes, PDI and surface
charge were detected during this period at the chosen condition. It could be of interest to
study the stability profile of these formulation at standard ambient temperature (25 ◦C)
to determine their shelf-life at higher temperature. Nonetheless, this could be concluded
based on the data obtained from this study that US along with HSH can be an effective
and fast method to prepare NLCs of varying particle sizes that can potentially improve the
dissolution rate of BCS II drugs.
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